Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy In patients aged 56 years and older with Acute Lymphoblastic leukemia (ALL).

    Summary
    EudraCT number
    2016-004836-39
    Trial protocol
    DE  
    Global end of trial date
    27 Oct 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    14 Nov 2024
    First version publication date
    14 Nov 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    Initial-1
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03460522
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Goethe University
    Sponsor organisation address
    Theodor-Stern-Kai 7, Frankfurt am Main, Germany,
    Public contact
    Medizinische Klinik II, Goethe Universität, 0049 6963016365, goekbuget@em.uni-frankfurt.de
    Scientific contact
    Medizinische Klinik II, Goethe Universität, 0049 6963016365, goekbuget@em.uni-frankfurt.de
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    30 Jul 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    30 Jun 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Oct 2023
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    Primary objective: To evaluate the efficacy of an inotuzumab ozogamicin induction therapy, defined as the number of patients being alive in first remission one year after start of induction therapy.
    Protection of trial subjects
    The study was performed in accordance with the requirements of the current German drug law (“Arzneimittelgesetz”), the current legal provisions regarding data protection, and the principals of Good Clinical Practice. Study personnel handled all patient data in a strictly confidential way. To prevent the identification of a person to whom study data belong, study data were pseudonymized by means of the patient identification number.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Aug 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 45
    Worldwide total number of subjects
    45
    EEA total number of subjects
    45
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    23
    From 65 to 84 years
    22
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    First patient in 06/13/2018, last patient out 08/02/2024 (MM/DD/YYYY)

    Pre-assignment
    Screening details
    Screening was conducted to verify that the inclusion criteria for the study were met. The unifying characteristics of the patient were age of ≥56 years and having a first diagnosis of a B precusor ALL(+CD22).

    Period 1
    Period 1 title
    Overall Trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded
    Blinding implementation details
    N.A. (open-label single-arm phase II study)

    Arms
    Arm title
    Inotuzumab Ozogamicin Induction Therapy
    Arm description
    All patients who receveid 2 or more cycles of inotuzumab ozogamicin therapy.
    Arm type
    open label single arm study

    Investigational medicinal product name
    Inotuzumab ozogamicin
    Investigational medicinal product code
    Other name
    BESPONSA®
    Pharmaceutical forms
    Powder for solution for infusion
    Routes of administration
    Intravenous use, Infusion
    Dosage and administration details
    Inotuzumab ozogamicin (PF-05208773), administrated as intravenous infusion over an hour. The dose for the three cycles were as follow: Cycle 1: Day 1 0.8mg/m2; day 8 and day 15 0.5mg/m2 Cycle 2 and 3: day 1, 8 and 15 dose of 0.5mg/m2

    Number of subjects in period 1
    Inotuzumab Ozogamicin Induction Therapy
    Started
    45
    Completed
    43
    Not completed
    2
         Consent withdrawn by subject
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall Trial
    Reporting group description
    -

    Reporting group values
    Overall Trial Total
    Number of subjects
    45 45
    Age categorical
    Units: Subjects
        Adults (56-64 years)
    23 23
        Adults (65-84 years)
    22 22
    Gender categorical
    Units: Subjects
        Female
    23 23
        Male
    22 22
    Subject analysis sets

    Subject analysis set title
    Evaluable patients
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    The population for the primary efficacy analysis by intention-to-treat (ITT) consists of all enrolled patients. Patients, who withdraw informed consent, are considered as screening failure due to violation of eligibility criteria, and patients who died prior to the first day of study intervention will not be included. This population is defined as full analysis set (FAS).

    Subject analysis sets values
    Evaluable patients
    Number of subjects
    43
    Age categorical
    Units: Subjects
        Adults (56-64 years)
    23
        Adults (65-84 years)
    20
    Age continuous
    Units:
        
    ( )
    Gender categorical
    Units: Subjects
        Female
    22
        Male
    21

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Inotuzumab Ozogamicin Induction Therapy
    Reporting group description
    All patients who receveid 2 or more cycles of inotuzumab ozogamicin therapy.

    Subject analysis set title
    Evaluable patients
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    The population for the primary efficacy analysis by intention-to-treat (ITT) consists of all enrolled patients. Patients, who withdraw informed consent, are considered as screening failure due to violation of eligibility criteria, and patients who died prior to the first day of study intervention will not be included. This population is defined as full analysis set (FAS).

    Primary: Event-free survival (EFS) at one year

    Close Top of page
    End point title
    Event-free survival (EFS) at one year [1]
    End point description
    End point type
    Primary
    End point timeframe
    12 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive analysis.
    End point values
    Evaluable patients
    Number of subjects analysed
    43
    Units: percent
    88
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Treatment phase + follow up
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    NCI CTCAE
    Dictionary version
    4.03
    Reporting groups
    Reporting group title
    All patients with study treatment
    Reporting group description
    All patients who received any infusion of the investigational drug.

    Serious adverse events
    All patients with study treatment
    Total subjects affected by serious adverse events
         subjects affected / exposed
    23 / 45 (51.11%)
         number of deaths (all causes)
    16
         number of deaths resulting from adverse events
    1
    Investigations
    LDH increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Neutropenia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Transfusion reaction
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Subarachnoid haemorrhage
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    Venoocclusive disease
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Surgical and medical procedures
    Kyphoplasty
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Presyncope
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Thrombocytopenia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Febrile neutropenia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Fever
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 45 (4.44%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ascites
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 45 (4.44%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Cysts ans fibroses in the gl. left parotid
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Shock haemorrhagic
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nausea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Retroperitoneal haemorrhage
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pleural effusion
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Acute Cystitis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Bronchial infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    bloodstreaminfection with E.coli, multiresistent
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    COVID-19 pneumonia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    2 / 45 (4.44%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    SARS-CoV-2 infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 45 (8.89%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Urosepsis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Fever of Unknown Origin
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urinary tract infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Hyperbilirubinaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    1 / 45 (2.22%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    All patients with study treatment
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    45 / 45 (100.00%)
    Investigations
    Alanine aminotransferase increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    20 / 45 (44.44%)
         occurrences all number
    30
    alkaline phosphatase increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 45 (11.11%)
         occurrences all number
    6
    AST, GOT increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    19 / 45 (42.22%)
         occurrences all number
    32
    Blood bilirubin increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    12 / 45 (26.67%)
         occurrences all number
    14
    GGT increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    6 / 45 (13.33%)
         occurrences all number
    13
    GOT/GPT increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    4
    Lipase increased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    7 / 45 (15.56%)
         occurrences all number
    11
    Neutrophil count decreased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    28 / 45 (62.22%)
         occurrences all number
    58
    Platelet count decreased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    36 / 45 (80.00%)
         occurrences all number
    83
    White blood cell count decreased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    38 / 45 (84.44%)
         occurrences all number
    79
    Vascular disorders
    Hypertension
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 45 (8.89%)
         occurrences all number
    10
    Hypotension
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 45 (8.89%)
         occurrences all number
    4
    thromboembolic event
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    6
    Antithrombin III decreased
    alternative assessment type: Non-systematic
         subjects affected / exposed
    7 / 45 (15.56%)
         occurrences all number
    17
    Nervous system disorders
    Headache
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 45 (11.11%)
         occurrences all number
    8
    Blood and lymphatic system disorders
    Anaemia/Hemoglobin
    alternative assessment type: Non-systematic
         subjects affected / exposed
    32 / 45 (71.11%)
         occurrences all number
    78
    Febrile neutropenia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 45 (11.11%)
         occurrences all number
    5
    General disorders and administration site conditions
    Edema limbs
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    4
    Pyrexia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    14 / 45 (31.11%)
         occurrences all number
    18
    Fatigue
    alternative assessment type: Non-systematic
         subjects affected / exposed
    7 / 45 (15.56%)
         occurrences all number
    11
    Gastrointestinal disorders
    Abdominal pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    7 / 45 (15.56%)
         occurrences all number
    7
    Ascites
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 45 (8.89%)
         occurrences all number
    6
    Diarrhoea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    4
    mucositis oral
    alternative assessment type: Non-systematic
         subjects affected / exposed
    8 / 45 (17.78%)
         occurrences all number
    8
    Nausea
    alternative assessment type: Non-systematic
         subjects affected / exposed
    7 / 45 (15.56%)
         occurrences all number
    8
    Stomach pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    4
    Respiratory, thoracic and mediastinal disorders
    Cough
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    3
    Epistaxis
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 45 (8.89%)
         occurrences all number
    7
    Renal and urinary disorders
    Acute kidney injury
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    11
    Musculoskeletal and connective tissue disorders
    Bone pain
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    5
    Infections and infestations
    Infection
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 45 (11.11%)
         occurrences all number
    5
    Metabolism and nutrition disorders
    Hypercalcaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 45 (8.89%)
         occurrences all number
    8
    Hyperglycaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    21 / 45 (46.67%)
         occurrences all number
    49
    Hyperuricaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    5 / 45 (11.11%)
         occurrences all number
    9
    Hypoalbuminaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    5
    Hypocalcaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    3 / 45 (6.67%)
         occurrences all number
    3
    Hypokalaemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    9 / 45 (20.00%)
         occurrences all number
    19
    Hypophosphataemia
    alternative assessment type: Non-systematic
         subjects affected / exposed
    9 / 45 (20.00%)
         occurrences all number
    14

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    01 Aug 2018
    Modifications of Protocol version1.4: - Prophylaxis: MTX dose changed from 15mg to 12mg - Clarification of asparaginase preparation: E.Coli asparaginase - Addition of Leukovorin-Rescue after HD-MTX according to GMALL recommendation
    31 Oct 2019
    Main modifications of protocol version 1.5: - Updates in the sypnose related to prephase and study treatment; - Update of cycle sequence (Ind I - III, Cons I + II, re-induction, Cons III - V, maintenance); - Data collection times adjusted (KMPs); - Changes in the days of the therapy cycles - The remission assessment was changed to the end of consolidation therapy 3 and 5 (before start of maintenance); - Updating the characterization of disease progression - Adverse events: progression and relapse of the disease under study was considered as an outcome not as an AE.
    31 Oct 2022
    The duration of the trial(8 years instead of 5), the statistics, the inclusion criteria, the rationale and the risk-benefit ratio were adapted accordingly as well as the time-schedule and the treatment plan. Inclusion criteria replaced: - patients aged 75 or older; -contraindications for intensive consolidation chemotherapy and/or severe comorbidities Exclusion criteria added: - COVID-19 infection at diagnosis therapy: -Standard of care - chemotherapy cycles consolidation I + II, reinduction, consolidation III - V omitted - Start of maintenance week 12 - Duration of aintenance: 20 months - Changes in the programming of intra-tax injections and remissions assessments. Updated definition of molecular response and time-dependent endpoints

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/37883727
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:37:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA